CHESHIRE, Conn., Nov. 9 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab) as a treatment for patients with PNH, have been published by the American Society of Hematology (ASH). Abstracts will be presented at the 2007 ASH annual meeting that is being held December 8 to 11, 2007 at the Georgia World Congress Center in Atlanta.
The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The abstracts and presentation information can be accessed at the links provided below.
http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5416http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5204http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5438
The following abstract will be presented in an oral session on red cell regulation and disorders of production on Tuesday, December 11, 2007. The abstract and presentation information can be accessed at the link provided below.
http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5302
CONTACT: Irving Adler, Sr. Director, Corporate Communications of Alexion
Pharmaceuticals, Inc., +1-203-272-8210; or Media, Mark Marmur of Makovsky &
Company, +1-212-508-9670; or Investors, Rhonda Chiger of Rx Communications,
+1-917-322-2569
